Altamira Therapeutics (NASDAQ:CYTO) issued a business update on Bentrio, its nasal spray for protection against airborne viruses and allergens. The company has set up contracts with wholesalers in its lead market of...
Cantor Fitzgerald initiated coverage of Vincerx Pharma (NASDAQ:VINC) with an “overweight” rating and $25 price target. The stock closed at $10.30 on Dec. 22. Vincerx is a clinical-stage oncology company that is on track...
Titan Pharmaceuticals (NASDAQ:TTNP) engaged Maxim Group as its exclusive financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be...
The FDA accepted Hepion Pharmaceuticals’ (NASDAQ:HEPA) IND application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC). Liver cancer is the sixth most...
H.C Wainwright initiated coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and price target of $9. The stock closed at $1.71 on Dec. 17. BioCardia is a clinical-stage company focused on the development of cell...
Maxim Group initiated coverage of Ayala Pharmaceuticals (NASDAQ:AYLA) with a “buy” rating and $22 price target. The stock closed at $9 on Dec. 17. Ayala is developing two gamma-secretase inhibitors – AL101 and...
H.C. Wainwright launched coverage of 89bio (NADAQ:ETNB) with a “buy” rating and price target of $46. The stock closed at $11.48 on Dec. 17. 89bio is a clinical-stage biopharmaceutical company focused on the development...
H.C. Wainwright initiated coverage of Vor Biopharma (NASDAQ:VOR) with a “buy” rating and $26 price target. The stock closed at $12.13 on Dec. 16. Vor is a clinical-stage cell therapy company focused on developing...
Cantor Fitzgerald launched coverage of Cardiol Therapeutics (NASDAQ:CRDL) with an “overweight” rating and price target of $8. The stock closed at $1.87 on Dec. 16. Cardiol is a clinical-stage, platform-enabled...
Altamira Therapeutics (NASDAQ:CYTO) randomized the first group of patients in a clinical trial with Bentrio (AM-301) in house dust mite allergic rhinitis. Bentrio, a drug-free nasal spray intended for personal...
Cidara Therapeutics (NASDAQ:CDTX) and Mundipharma reported positive topline data from the ReSTORE Phase 3 clinical trial, evaluating the efficacy and safety of its once-weekly antifungal...
H.C. Wainwright initiated coverage of Virios Therapeutics (NASDAQ:VIRI) with a “buy” rating and price target of $12. The stock closed at $4.58 on Dec. 14. Virios is a clinical-stage biotech company developing a novel...